ArticleFrontiers in digital health2026
Patient-reported first-use usability of the noncommercial MyTARGET mobile application among adults with inflammatory bowel disease: a cross-sectional survey.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mobile health applications may support self-management in inflammatory bowel diseases (IBD), but evidence on first-use experiences with disease-specific mobile health applications is limited. Objective: To evaluate first-use usability of the noncommercial MyTARGET mobile application among adults with IBD in Germany and identify priorities for refinement. Methods: In this single-center cross-sectional usability survey, adults with Crohn's disease or ulcerative colitis installed MyTARGET on their own smartphones, received a 15-minute standardized introduction and independently explored the application for 45 min during one outpatient session. Participants completed a 13-item questionnaire adapted from the German Telehealth Usability Questionnaire on a 7-point Likert scale. Recommendation intention was assessed using the Net Promoter Score (NPS). Results: All 200 participants completed the questionnaire (mean age 39.1 years; SD, 14.0; 48.0% female); 127/200 (63.5%) had Crohn's disease and 73/200 (36.5%) had ulcerative colitis. Mean overall usability was 6.00 (SD, 0.57; 95% CI, 5.92-6.08). User-friendliness (mean, 6.65; SD, 0.61) and ease of learning (mean, 6.41; SD, 0.59) received the highest ratings, whereas error handling/troubleshooting (mean, 5.59; SD, 0.93) and perceived time savings were lower. The Net Promoter Score was +16 points. Overall usability correlated with recommendation score (Spearman Conclusions: MyTARGET showed high patient-reported first-use usability in this selected outpatient sample. The findings identify aspects that could inform future refinement and suggest that ease of use alone may not determine willingness to recommend an IBD app.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.